Skip to main content
Subscribe
Register
Sign in
Membership
Events
Knowledge Center
About
Subscribe
Register
Sign in
Hedge Funds
Latest Articles
With a Thin IPO Calendar, Hedge Funds Are Zeroing In on Biopharma
Stephen Taub
January 29, 2026
Premium
The Lowdown on High Ground’s Best Year
Stephen Taub
January 26, 2026
Premium
How Electron Is Rewiring Its Portfolio This Year After a Muted Finish to 2025
Stephen Taub
January 20, 2026
Chris Hohn’s TCI Tops Hedge Fund Gains in 2025
Michelle Celarier
January 19, 2026
Premium
From Deep Losses to Remarkable Gains: Biopharma’s Wildest Year in Recent Memory
Stephen Taub
January 14, 2026
Premium
Caxton and Graham Post Solid Gains in a Strong Year for Macro Funds
Stephen Taub
January 13, 2026
Premium
Valiant Topped the Tiger Crowd in 2025
Stephen Taub
January 12, 2026
Behind Bridgewater’s Surge
Stephen Taub
January 8, 2026
The ‘Precarious’ Risk-On Strategy That Drove Seawolf’s Outperformance
Michelle Celarier
January 7, 2026
Premium
Jericho’s Three-Year Hot Streak Shows No Signs of Cooling
Stephen Taub
January 7, 2026
Premium
Light Street Caps Big Year After Dialing Back Chip Bets
Stephen Taub
January 6, 2026
Seed Funding Isn’t Small Anymore: AI Start-Ups Push Rounds to Historic Highs
Stephen Taub
December 18, 2025
Premium
Hedge Funds Miss 2025’s Biggest Stock Surges
Stephen Taub
December 17, 2025
Premium
Biopharma Specialist Cormorant Plans New $125 Million Blank-Check Venture
Stephen Taub
December 16, 2025
Premium
Hedge Funds Hope to Cash In on Perceptive Advisors’ SPAC
Stephen Taub
December 15, 2025
Biopharma Funds Deliver Market-Beating Returns as Valuations Snap Back
Stephen Taub
December 11, 2025
Premium
Ex-TCI Partner Edgar Allen’s High Ground Racks Up Record Year
Stephen Taub
December 9, 2025
Premium
Renaissance’s Public Funds Stage Double-Digit Comeback in November
Stephen Taub
December 8, 2025
More Articles